AbbVie failed to secure a judicial injunction overturning Missouri's regulation of 340B contract pharmacy practices, facing a second legal defeat in weeks related to the federal 340B drug pricing program. The company had contested alleged abuses impacting pricing and discounts under the program. This ruling signals continued scrutiny of contract pharmacy arrangements and may impact drug manufacturers' ability to control pricing under federal programs, highlighting ongoing tensions between payers, providers, manufacturers, and regulators over drug cost management.